fda semaglutide warning news october 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" FDA Approves First Oral GLP-1

GLP-1 medications can help offset some of these changes

Because the medication does not encourage sustainable, positive lifestyle change, its common to regain the weight after stopping the medication

What may change after approval If retatrutide reaches FDA approval, the pricing conversation could shift from a patchwork of self-pay options toward a more familiar system

Proper preparation of your environment significantly reduces the risk of introducing contaminants that could compromise the safety of your medication or cause injection site reactions

An enzyme called dipeptidyl peptidase-4 (DPP-4) rapidly metabolizes GLP-1, rendering it inactive

This model eliminates the need for waiting rooms and allows for consistent, ongoing support